Benchmark Financial Wealth Advisors LLC Acquires New Position in Pfizer Inc. (NYSE:PFE)

Benchmark Financial Wealth Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFEFree Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 8,149 shares of the biopharmaceutical company’s stock, valued at approximately $235,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Norges Bank acquired a new stake in Pfizer during the 4th quarter valued at $3,150,472,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the last quarter. Morgan Stanley increased its stake in shares of Pfizer by 10.3% in the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Pfizer in the first quarter worth $311,238,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock traded down $0.17 during midday trading on Tuesday, hitting $27.55. 30,662,538 shares of the company were exchanged, compared to its average volume of 43,380,047. The firm has a market capitalization of $156.00 billion, a P/E ratio of 76.53, a PEG ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm’s 50 day moving average price is $27.43 and its two-hundred day moving average price is $29.29. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Truist Financial reduced their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

Read Our Latest Research Report on PFE

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.